West Pharmaceutical Services Bilan de santé
Santé financière contrôle des critères 6/6
West Pharmaceutical Services possède un total de capitaux propres de $2.8B et une dette totale de $202.6M, ce qui porte son ratio d'endettement à 7.4%. Son actif total et son passif total sont $3.7B et de $923.0M. L'EBIT de West Pharmaceutical Services est $594.1M ce qui fait que son ratio de couverture des intérêts -30.9. Elle dispose de liquidités et de placements à court terme de $490.9M.
Informations clés
7.4%
Ratio d'endettement
US$202.60m
Dette
| Ratio de couverture des intérêts | -30.9x |
| Argent liquide | US$490.90m |
| Fonds propres | US$2.75b |
| Total du passif | US$923.00m |
| Total des actifs | US$3.68b |
Mises à jour récentes de la santé financière
We Think West Pharmaceutical Services (NYSE:WST) Can Stay On Top Of Its Debt
Jun 27
Is West Pharmaceutical Services (NYSE:WST) A Risky Investment?
Mar 12West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet
Nov 27Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
Aug 22Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
May 16West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet
Jan 31Recent updates
Should You Think About Buying West Pharmaceutical Services, Inc. (NYSE:WST) Now?
Nov 15West Pharmaceutical Services, Inc. Just Recorded A 27% EPS Beat: Here's What Analysts Are Forecasting Next
Oct 27West Pharma's Destocking Dilemma: Why Staying On The Sidelines Makes Sense
Oct 11Getting In Cheap On West Pharmaceutical Services, Inc. (NYSE:WST) Is Unlikely
Sep 20A Look At The Intrinsic Value Of West Pharmaceutical Services, Inc. (NYSE:WST)
Sep 02West Pharmaceutical Services, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
Jul 28West Pharmaceutical: Continued Destocking And A High Valuation Post Q2 Results (Rating Maintained)
Jul 25Is It Time To Consider Buying West Pharmaceutical Services, Inc. (NYSE:WST)?
Jul 15We Think West Pharmaceutical Services (NYSE:WST) Can Stay On Top Of Its Debt
Jun 27Estimating The Fair Value Of West Pharmaceutical Services, Inc. (NYSE:WST)
May 21West Pharmaceutical: Pick And Shovels Of The Injectable Drug Industry
May 11West Pharmaceutical Services, Inc.'s (NYSE:WST) Business Is Yet to Catch Up With Its Share Price
Mar 30Is West Pharmaceutical Services (NYSE:WST) A Risky Investment?
Mar 12Why West Pharma Is Far From Done
Feb 28West Pharmaceutical Services, Inc.'s (NYSE:WST) Intrinsic Value Is Potentially 19% Below Its Share Price
Feb 20West Pharmaceutical Services: Still Too Expensive After The Recent Drop
Feb 20What Does West Pharmaceutical Services, Inc.'s (NYSE:WST) Share Price Indicate?
Jan 10West Pharmaceutical: Great Business, Not So Great Valuation
Jan 08What West Pharmaceutical Services, Inc.'s (NYSE:WST) P/E Is Not Telling You
Dec 18West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet
Nov 27West Pharmaceutical Services: The Run Might Be Over
Oct 18Is West Pharmaceutical Services, Inc. (NYSE:WST) Potentially Undervalued?
Sep 24Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
Aug 22West Pharmaceutical: Revise To Buy On Exceptional Economic Characteristics
Aug 08What Is West Pharmaceutical Services, Inc.'s (NYSE:WST) Share Price Doing?
Jun 26West Pharmaceutical: Hard To Justify The Price
May 26Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
May 16At US$330, Is It Time To Put West Pharmaceutical Services, Inc. (NYSE:WST) On Your Watch List?
Mar 20West Pharmaceutical Services' (NYSE:WST) Soft Earnings Don't Show The Whole Picture
Feb 28West Pharmaceutical Q4 2022 Earnings Preview
Feb 15West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet
Jan 31West Pharmaceutical: An Earnings Decline Seen In 2023, Shares Still Appear Expensive
Dec 19West Pharmaceutical declares $0.19 dividend
Dec 13Why West Pharmaceutical Services, Inc. (NYSE:WST) Could Be Worth Watching
Nov 29Analyse de la situation financière
Passif à court terme: Les actifs à court terme de WST ( $1.6B ) dépassent ses passifs à court terme ( $516.5M ).
Passif à long terme: Les actifs à court terme de WST ( $1.6B ) dépassent ses passifs à long terme ( $406.5M ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: WST dispose de plus de liquidités que de sa dette totale.
Réduire la dette: Le ratio d'endettement de WST a été réduit de 13.1% à 7.4% au cours des 5 dernières années.
Couverture de la dette: La dette de WST est bien couverte par le flux de trésorerie opérationnel ( 346.7% ).
Couverture des intérêts: WST gagne plus d'intérêts qu'il n'en paie, donc la couverture des paiements d'intérêts n'est pas un problème.